D-0263-2021 Class II Terminated
FDA drug recall D-0263-2021 was initiated by Ascend Laboratories LLC on Jan 22, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit. The recall status is terminated (terminated Dec 2, 2022). Affected quantity: 14,205 100 mL bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 24, 2021
- Initiation Date
- Jan 22, 2021
- Termination Date
- Dec 2, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 14,205 100 mL bottles
Product description
Cephalexin for Oral Suspension, USP 250 mg per 5 mL, 100 ml (when mixed) Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-88
Reason for recall
CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.
Distribution pattern
Nationwide in the USA
Code information
Lot # 19144841, Exp 9/2021; 20141673 Exp 4/2022.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0263-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026